Aquinox Pharma’s Phase 1 AQX-1125 is a three part study in healthy volunteers.
The primary objectives of Phase I are to evaluate the safety, tolerability and pharmacokinetics of AQX-1125 administered orally once-daily.
Additionally, the secondary objective includes investigating the pharmacodynamics of AQX-1125 through the utilization of biomarkers.
Aquinox Pharma chairman, president and CEO David Main said that AQX-1125 has demonstrated efficacy in preclinical models of inflammatory disease and has desirable pharmaceutical properties making it a strong development candidate.
Aquinox chief medical officer David Chernoff said that the Phase I study will enroll 52 normal health volunteers at a single center in Europe.
"We believe this study will provide us with the data necessary to progress our clinical programs forward into multiple proof-of-concept studies in different indications," Chernoff said.